Please login to the form below

Not currently logged in
Email:
Password:

Double-dose of cancer drug fails to meet target

Novartis has failed to prove that higher measures of its cancer drug, Glivec are more effective than the current dosage
Novartis has failed to prove in clinical trials that higher measures of its cancer drug, Glivec are more effective than the current dosage.

Trials of 800mg doses of Glivec in patients with chronic myeloid leukaemia (CML), showed no statistically significant improvement to patients treated with the standard 400mg dose.

The higher dose did however have an effect when used as the primary treatment for newly diagnosed patients with clinical milestones achieved significantly faster than with the 400mg dose.

"[The trial] reaffirms Glivec as the standard of care for newly diagnosed CML patients," said Dr Jorge Cortes, professor of medicine and deputy chair of Leukemia at the University of Texas. "We see a strong trend for rapid response with the 800mg doseÖ further follow up will be needed to assess what this rapid early response will mean in terms of long-term benefit."

13th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics